BioSpace News Archive

Merck announced today that Robert M. Davis, chief financial offer and executive vice president, Merck Global Services, is scheduled to present at Citi’s 2018 Global Healthcare Conference in New York on Dec. 5, 2018 at 8:45 a.m. EST.

Customizable Skin Treatments Address Patient-Specific Concerns

Vital Scout now available on Amazon and holiday promotions underway across e-commerce options

Plex is preparing to advance CAP1160 into in vivo animal studies for preclinical efficacy and proof of concept

Sangamo Therapeutics, Inc. today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.

Topics to include DNA and RNA profiling and next-generation sequencing of tumors

KemPharm, Inc. today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.

Allele uses experts from Scientist.com’s Genius Consulting NetworkTM and proprietary internal technology to create innovative biologics programs

MYM Nutraceuticals Inc. is pleased to announce the Company has signed a term sheet for a $25 million equity investment by Alumina Partners LLC, a New York-based private equity firm that has made substantial investments in the cannabis space.

Aegis’ Intravail® drug delivery technology utilized in Neurelis’ VALTOCO™ Nasal Spray, a novel investigational treatment for epilepsy patients [03-December-2018] SAN DIEGO , Dec. 3, 2018 /PRNewswire/ -- Neurelis, Inc. today announced the acquisition of Aegis Therapeutics, a San Diego -based drug delivery technology company. Aegis Therapeutics’ proprietary portfol